We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter – – Approximately 50% of participants have compensated cirrhosis – Vir Biotechnology, Inc...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
As filed with the Securities and Exchange Commission on February 26, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
0001706431false2023FYP3YP7YP7Yhttp://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilitieshttp://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities43800017064312023-01-012023-12-3100...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen 44th Annual Health...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -1.45914396887 | 10.28 | 10.48 | 9.78 | 680097 | 10.05389974 | CS |
4 | -1.61 | -13.7137989779 | 11.74 | 11.82 | 9.77 | 943436 | 10.69971123 | CS |
12 | -0.01 | -0.0986193293886 | 10.14 | 12 | 8.415 | 1112173 | 10.21827506 | CS |
26 | 0.88 | 9.51351351351 | 9.25 | 12 | 7.72 | 1162693 | 9.6346231 | CS |
52 | -12.75 | -55.7255244755 | 22.88 | 27.48 | 7.72 | 1184641 | 13.54025451 | CS |
156 | -40.65 | -80.0512012603 | 50.78 | 58 | 7.72 | 1142767 | 25.73170819 | CS |
260 | -6.02 | -37.2755417957 | 16.15 | 141.01 | 7.72 | 1133421 | 30.97495995 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions